- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Karyopharm Therapeutics is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.64 – a decrease of 9.29% over the previous week. Karyopharm Therapeutics employs 325 staff and has a trailing 12-month revenue of around $148.4 million.
Our top picks for where to buy Karyopharm Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Karyopharm Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – KPTI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Karyopharm Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Karyopharm Therapeutics stock price (NASDAQ: KPTI)
Use our graph to track the performance of KPTI stocks over time.Karyopharm Therapeutics shares at a glance
Information last updated 2024-12-18.
| Latest market close | $0.64 |
|---|---|
| 52-week range | $0.64 - $1.95 |
| 50-day moving average | $0.83 |
| 200-day moving average | $0.97 |
| Wall St. target price | $4.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.05 |
Is it a good time to buy Karyopharm Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Karyopharm Therapeutics price performance over time
Historical closes compared with the close of $0.635 from 2024-12-20
| 1 week (2024-12-13) | -9.29% |
|---|---|
| 1 month (2024-11-22) | -24.85% |
| 3 months (2024-09-20) | -13.96% |
| 6 months (2024-06-21) | -34.91% |
| 1 year (2023-12-22) | -22.94% |
|---|---|
| 2 years (2022-12-22) | -76.57% |
| 3 years (2021-12-22) | 7.13 |
| 5 years (2019-12-20) | 18.35 |
Karyopharm Therapeutics financials
| Revenue TTM | $148.4 million |
|---|---|
| Gross profit TTM | $151.9 million |
| Return on assets TTM | -34.27% |
| Return on equity TTM | -891.05% |
| Profit margin | -58.93% |
| Book value | $-1.27 |
| Market Capitalization | $83.6 million |
TTM: trailing 12 months
Karyopharm Therapeutics share dividends
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Karyopharm Therapeutics share price volatility
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $0.635 up to $1.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.154. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).
Karyopharm Therapeutics overview
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Frequently asked questions
What percentage of Karyopharm Therapeutics is owned by insiders or institutions?Currently 6.25% of Karyopharm Therapeutics shares are held by insiders and 48.577% by institutions. How many people work for Karyopharm Therapeutics?
Latest data suggests 325 work at Karyopharm Therapeutics. When does the fiscal year end for Karyopharm Therapeutics?
Karyopharm Therapeutics's fiscal year ends in December. Where is Karyopharm Therapeutics based?
Karyopharm Therapeutics's address is: 85 Wells Avenue, Newton, MA, United States, 02459-3298 What is Karyopharm Therapeutics's ISIN number?
Karyopharm Therapeutics's international securities identification number is: US48576U1060 What is Karyopharm Therapeutics's CUSIP number?
Karyopharm Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576U106
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question